Roland Zahn
A5036810313- SARS-CoV-2 and COVID-19 Research
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- COVID-19 Clinical Research Studies
- Virus-based gene therapy research
- HIV Research and Treatment
- Immune Cell Function and Interaction
- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Animal Virus Infections Studies
- Virology and Viral Diseases
- SARS-CoV-2 detection and testing
- Influenza Virus Research Studies
- Platelet Disorders and Treatments
- Viral Infections and Immunology Research
- Hepatitis B Virus Studies
- vaccines and immunoinformatics approaches
- Cytomegalovirus and herpesvirus research
- COVID-19 epidemiological studies
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Long-Term Effects of COVID-19
- Heparin-Induced Thrombocytopenia and Thrombosis
- Mosquito-borne diseases and control
- RNA Interference and Gene Delivery
Janssen (Netherlands)
2015-2024
Johnson & Johnson (Netherlands)
2015-2024
Janssen (Switzerland)
2022
Janssen (Belgium)
2020
Goethe University Frankfurt
1958-2019
Beth Israel Deaconess Medical Center
2008-2016
Harvard University
2008-2011
Georg Speyer Haus
2006-2009
Heart and Diabetes Center North Rhine-Westphalia
2000
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has made the development of a vaccine top biomedical priority. In this study, we developed series DNA candidates expressing different forms SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals humoral cellular immune responses, including neutralizing antibody titers at levels comparable to those found convalescent humans macaques infected...
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global disease 2019 (COVID-19) pandemic. A key unanswered question whether infection with SARS-CoV-2 results in against reexposure. We developed a rhesus macaque model observed that macaques had high viral loads upper lower tract, humoral cellular immune responses, pathologic evidence pneumonia. After initial...
Development of effective preventative interventions against SARS-CoV-2, the etiologic agent COVID-19 is urgently needed. The viral surface spike (S) protein SARS-CoV-2 a key target for prophylactic measures as it critical replication cycle and primary neutralizing antibodies. We evaluated design elements previously shown other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions heterologous signal peptides, selection S-based vaccine candidate. In...
Abstract Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the leading cause of infant hospitalizations. Recently, a promising vaccine antigen based on RSV fusion protein (RSV F) stabilized in native prefusion conformation has been described. Here we report alternative strategies to arrest F prevention hinge movements first refolding region elimination proteolytic exposure peptide. A limited number unique mutations are identified that stabilize...
Abstract Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death 1–4 . Studies of acute syndrome coronavirus 2 (SARS-CoV-2) infection hamsters 5–7 nonhuman primates 8–10 have generally reported clinical disease, preclinical SARS-CoV-2 vaccine studies demonstrated reduction viral replication the upper lower tracts 11–13 Here we show that high-dose intranasal results including high levels...
Abstract A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with Omicron subvariants 1,2 , although still severe disease. Enhanced mucosal immunity may be required to block and onward transmission. Intranasal administration has proven inconsistent 3–7 suggesting alternative immunization strategies required. Here we show intratracheal boosting a bivalent Ad26-based vaccine results in substantial induction humoral cellular near-complete BQ.1.1...
We describe a genome reference of the African green monkey or vervet (Chlorocebus aethiops). This member Old World (OWM) superfamily is uniquely valuable for genetic investigations simian immunodeficiency virus (SIV), which it most abundant natural host species, and wide range health-related phenotypes assessed in Caribbean vervets (C. a. sabaeus), whose numbers have expanded dramatically since Europeans introduced small their ancestors from West Africa during colonial era. use to...
The search for a universal filovirus vaccine that provides protection against multiple species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic should be able to provide all known as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity elicited multivalent vaccines expressing glycoproteins (GP) Ebola (EBOV), Sudan (SUDV), Taï Forest (TAFV) Marburg (MARV). Immune responses GP...
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve magnitude durability of immunity protective efficacy. We assessed one- two-dose Ad26.COV2.S candidate in adult aged nonhuman primates (NHPs). A regimen induced higher peak binding neutralizing antibody responses compared with a single dose. In one-dose regimens, were stable for at least...
Zika virus (ZIKV) may cause severe congenital disease after maternal-fetal transmission. No vaccine is currently available.To assess the safety and immunogenicity of Ad26.ZIKV.001, a prophylactic ZIKV candidate.Phase 1 randomized, double-blind, placebo-controlled clinical study. (ClinicalTrials.gov: NCT03356561).United States.100 healthy adult volunteers.Ad26.ZIKV.001, an adenovirus serotype 26 vector encoding M-Env, administered in 1- or 2-dose regimens 5 × 1010 1011 viral particles (vp),...
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly MARV vaccine “MARVAC” consortium representing leaders field research development aiming to facilitate a rapid response this infectious disease threat. Here, we discuss current progress, challenges, future directions for vaccines.
The prefusion conformation of human metapneumovirus fusion protein (hMPV Pre-F) is critical for eliciting the most potent neutralizing antibodies and preferred immunogen an efficacious vaccine against hMPV respiratory infections. Here we show that additional cleavage event in F allows closure correct folding trimer. We therefore engineered to undergo double cleavage, which enabled screening Pre-F stabilizing substitutions at natively folded protomer interfaces. To identify these...
Abstract It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of data, immunobridging is an approach infer likelihood a vaccine protective effect, by translating immunogenicity in humans using relationship between and desired outcome suitable animal model. We here propose effect Ad26.ZEBOV, MVA-BN-Filo regimen with 8-week interval immunobridging. Immunogenicity data were obtained Ad26.ZEBOV regimens fully lethal EBOV Kikwit...
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster non-human primate infection models. Here, investigated the immunogenicity, protective efficacy, potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S moderate challenge model, using currently most prevalent G614 variant. Vaccine...
The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy current COVID-19 vaccines
Omicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously immunized with Ad26.COV2.S, boosted Ad26.COV2.S.529 (encoding BA.1 S) or 1:1 combination of both vaccines. All booster vaccinations elicit rapid antibody titers increase WA1/2020 and S. BA.2 responses most effectively by including Ad26.COV2.S.529. Independent used, mostly WA1/2020-reactive WA1/2020-Omicron cross-reactive B...
Abstract The spike protein (S) of SARS-CoV-2 induces neutralizing antibodies and is the key component current COVID-19 vaccines. most efficacious vaccines are genetically-encoded spikes with a double proline substitution in hinge region to stabilize S prefusion conformation (S-2P). A subunit vaccine can be valuable addition mRNA viral vector-based but requires high stability spike. In addition, further stabilization might improve immunogenicity. To test this, five proteins were designed...
Filoviruses cause sporadic but highly lethal outbreaks of hemorrhagic fever in Africa the human population. Currently, no drug or vaccine is available for treatment prevention. A previous study with a candidate based on low seroprevalent adenoviruses 26 and 35 (Ad26 Ad35) was shown to provide protection against homologous Ebola Zaire challenge non primates (NHP) if applied prime-boost regimen. Here we have aimed expand this principle construct evaluate Ad26 Ad35 vectors development universal...
RSV is an important cause of lower respiratory tract infections in children, the elderly and those with underlying medical conditions. Although high disease burden indicates urgent need for a vaccine against RSV, no licensed currently available. We developed candidate based on low-seroprevalent human adenovirus serotypes 26 35 (Ad26 Ad35) encoding fusion (F) gene. Single immunization mice either one these vectors induced titers neutralizing antibodies levels F specific...
In 2015, there was a large outbreak of Zika virus (ZIKV) in Brazil. Despite its relatively mild impact on healthy adults, ZIKV infection during pregnancy has been associated with severe birth defects. Currently, is no vaccine available, but several candidates based the membrane (M) and envelope (Env) structural proteins showed promising results preclinical clinical studies. Here, immunogenicity protective efficacy non-replicating adenoviral vector type 26 (Ad26) that encodes M-Env antigens...
Immunity from prior infection or Ad26.COV2.S vaccination protected hamsters challenge with a heterologous strain of SARS-CoV-2 5 weeks later.